Four individually druggable MET hotspots mediate HGF-driven tumor progression. - Wikidata - awgldk - TriplyDB

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

http://www.wikidata.org/entity/Q30581656

about

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.Mechanisms of action of therapeutic antibodies for cancer MET-activating Residues in the B-repeat of the Listeria monocytogenes Invasion Protein InlB.Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform.Achieving high signal-to-noise in cell regulatory systems: Spatial organization of multiprotein transmembrane assemblies of FGFR and MET receptors.Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity.Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain.Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3.Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.

P2860

Q26799900-CD2D1BA4-3708-41A2-BC22-38797436A2D4 Q27316983-9A48DC7A-3BE3-41E7-9F93-1D5F15895956 Q28385366-3F1620BC-CED0-4E56-BE9D-51478A5F6F3B Q30394618-5BE84F19-8ED6-4E28-9C8F-750203AA92FB Q33888739-3E89547D-111C-491D-921F-AA74EE27B6AF Q35946548-7FCC64D0-354C-4757-A048-374146979C3F Q36214456-28BA9042-2242-4946-92FB-FEED472809FD Q36798972-BD95558C-FF10-4821-AB12-1AB32A8F4508 Q36863246-11C1132A-AA10-4E01-A9BF-FA8C11D9F981 Q37141597-E42543A3-539D-4C8B-B765-FC1391767FC6 Q38874084-045E0DE8-2EBB-46ED-91A9-01AB2BE6F7B2 Q41293978-24F0A243-35F8-4BD5-A234-07E0DFC6E262 Q41490164-202084AA-0754-4E66-A23B-DCB1A6DD732A Q41660598-EA533717-CD93-4993-B11B-4DA43476E8A7 Q42499937-782322DE-839F-4B77-9854-F6DCBF8967C9 Q42650625-39F21960-58B6-42F2-AB33-4524A0395AAC Q52679662-073EEB7D-B0DD-4BC6-86C6-781BF30908C5 Q53789447-D830E66D-6899-44CC-AD0F-9614B31F6891

P2860

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

http://www.wikidata.org/entity/Q30581656

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

@ast

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

@en

type

label

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

@ast

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

@en

prefLabel

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

@ast

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

@en

P1433

Q30581656-5055E563-1B15-4908-A3C9-225605CFB938

P1476

Q30581656-9AA2EA72-D74F-4D36-9D9E-CA8AB6544393

P2093

Q30581656-4EEBCB88-B1E9-49C7-945D-416F01A57F73

Q30581656-678B6BD9-9A07-44BC-8951-7165F10A5347

Q30581656-81496879-B253-4CD6-BB31-826AFC692ECC

Q30581656-88757FB0-45CC-4EED-8921-FA4ED382A1E3

Q30581656-8EC64475-A4F0-4C1E-B239-503E5948DD93

Q30581656-AAEADC4D-B1AC-4DEC-85D3-DB2812B680F1

Q30581656-AB19656F-D020-4F3C-B35D-5806C0EFED8C

Q30581656-B1865C72-DE8B-4306-A1B6-1EC0AB0F2AD7

Q30581656-C00814E6-60DB-4E6C-8FF4-4011EDC7C495

Q30581656-D6FFCCC4-66FA-4681-89EF-5A55212E181F

P2860

Q30581656-0209283C-8299-4204-A85A-EAFA1D1C904B

Q30581656-04E61B35-FB18-4CD7-8057-C1047FA40D04

Q30581656-054A8B91-2BA9-42E1-8C13-8B949E061F8C

Q30581656-1395E3BC-101F-4725-84DC-93D823A2B30F

Q30581656-2248C038-E6C1-406A-AD5F-C78E8076681E

Q30581656-266B5A0C-B529-4201-9F70-EA6DC53F77D1

Q30581656-28C08196-9F3B-4F56-8D04-2B7841C3AF9D

Q30581656-2AFDF172-657F-423E-81A7-08E50C4319E4

Q30581656-2D7AE8A7-330E-4E4D-B869-715B8F585FF1

Q30581656-2EC8235B-B2EF-4460-AE3D-7537BD3E0A2A

P304

Q30581656-21829E76-AE52-4B79-8858-7538C4C83757

P31

Q30581656-2F7C029F-CE9B-470A-B3D7-B5408F966ABB

P356

Q30581656-C608E5C5-CD68-446B-89E3-C6B314428D81

P407

Q30581656-90227A89-7944-4FF2-978A-22D353EBE69B

P433

Q30581656-F160CB24-BD3B-4514-98C7-DCAA6438F917

P478

Q30581656-853D530B-BA25-41F8-8A1F-49B7443AC3A5

P50

Q30581656-B523E987-4DE6-4908-87CF-FB2706662677

Q30581656-B9A6C22A-58BD-43C4-827D-0D89C0A8700A

Q30581656-FC007893-0656-4599-BD4D-F5C954AC6354

P577

Q30581656-5732A411-EE9B-4BDA-BFE5-C8803F42D214

P698

Q30581656-927EEE4E-CED8-411D-AD66-F59D53CDF532

P932

Q30581656-08299BCC-3CDB-4B3F-97B6-1025E56DF616

P356

P1433

Journal of Clinical Investigation

P1476

Four individually druggable MET hotspots mediate HGF-driven tumor progression

@en

P2093

Anna Hultberg

http://www.w3.org/2001/XMLSchema#string

Christophe Blanchetot

http://www.w3.org/2001/XMLSchema#string

Cristina Basilico

http://www.w3.org/2001/XMLSchema#string

Els Festjens

http://www.w3.org/2001/XMLSchema#string

Gitte De Boeck

http://www.w3.org/2001/XMLSchema#string

Hans de Haard

http://www.w3.org/2001/XMLSchema#string

Michael Saunders

http://www.w3.org/2001/XMLSchema#string

Natalie de Jonge

http://www.w3.org/2001/XMLSchema#string

Paolo Michieli

http://www.w3.org/2001/XMLSchema#string

Sjudry-Ilona Osepa

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Met, metastasis, motility and more

Invasive growth: a MET-driven genetic programme for cancer and stem cells

P304

3172-3186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI72316

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Virginia Morello

Manuela Cazzanti

P577

2014-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24865428

http://www.w3.org/2001/XMLSchema#string

P932

4071368

http://www.w3.org/2001/XMLSchema#string